Gynecology

New treatment for symptoms of premenstrual dysphoric disorder

Published in Women's Health Weekly, June 19th, 2003

Analysis of three placebo-controlled studies, presented at the American Psychiatric Association annual meeting, demonstrate that Paxil CR (paroxetine HCl) controlled release is effective in treating the emotional symptoms of premenstrual dysphoric disorder (PMDD), including irritability, tension, and depressed mood, as well as the associated physical symptoms.

The lowest dose of Paxil CR, 12.5 mg per day, was shown to reduce overall symptoms and was well-tolerated with a low rate of patient drop outs. Similar results were seen with 25mg per day dose. Paxil CR is currently under review by the U.S. Food and Drug Administration as a treatment for PMDD.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry